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Sensory impairments constitute core dysfunctions in schizophrenia. In the auditory modality, 40 
impaired mismatch negativity (MMN) has been observed in chronic schizophrenia and may reflect 41 
N-methyl-D-aspartate (NMDA) hypo-function, consistent with models of schizophrenia based on 42 
oxidative stress. Moreover, a recent study demonstrated deficits in the N100 component of the 43 
auditory evoked potential (AEP) in early psychosis patients. Previous work has shown that add-on 44 
administration of the glutathione precursor N-acetyl-cysteine (NAC) improves the MMN and clinical 45 
symptoms in chronic schizophrenia. To date, it remains unknown whether NAC also improves 46 
general low-level auditory processing and if its efficacy would extend to early-phase psychosis. We 47 
addressed these issues with a randomized, double-blind study of a small sample (N=15) of early 48 
psychosis (EP) patients and 18 healthy controls from whom AEPs were recorded during an active, 49 
auditory oddball task. Patients were recorded twice: once prior to NAC/placebo administration and 50 
once after six months of treatment. The N100 component was significantly smaller in patients 51 
before NAC administration versus controls. Critically, NAC administration improved this AEP deficit.  52 
Source estimations revealed increased activity in the left temporo-parietal lobe in patients after 53 
NAC administration. Overall, the data from this pilot study, which call for replication in a larger 54 
sample, indicate that NAC improves low-level auditory processing in early psychosis. 55 
56 
1. Introduction 57 
 Low-level sensory impairments, both in auditory and in visual processing, seem to constitute part 58 
of the core dysfunctions in schizophrenia (Ethridge et al., 2015, Javitt and Freedman, 2015; Javitt, 59 
2009). Increasing evidence indicates that oxidative stress related to glutathione (GSH) synthesis 60 
deficits in conjunction with N-methyl-D-aspartate (NMDA) hypofunction are major contributors to 61 
the pathophysiology of schizophrenia (Hardingham and Do, 2016). Previous work has shown that 62 
add-on administration of the glutathione precursor NAC in chronic schizophrenia patients improves 63 
auditory MMN generation to tone deviants (Lavoie et al., 2008) and clinical symptoms (Berk et al., 64 
2008). However, it remains unknown whether NAC can also improve general low-level auditory 65 
processing impairments and whether its efficacy extends to the early stages of the disease. The 66 
contribution of an impaired antioxidant system in schizophrenia is supported by a variety of 67 
findings. Polymorphisms in key genes for GSH synthesis have been associated with schizophrenia 68 
(Rodriguez-Santiago et al., 2010; Do et al, 2009; Gysin et al., 2007; Tosic et al., 2006) and are related 69 
with decreased GSH levels in the cerebrospinal fluid, prefrontal cortex and post-mortem caudate of 70 
patients (Do et al., 2000; Yao et al., 2006; Flatow et al., 2013; Gawryluk et al., 2011; Xin e al., 2016; 71 
for a review see Koga et al., 2016; Yao and Keshavan, 2011). GSH-deficient animal models 72 
reproduce schizophrenia phenotypes including hypofunction of NMDA receptors (NMDAR) (Steullet 73 
et al., 2006). Several studies have demonstrated that the administration of NMDAR agonists 74 
induces in healthy controls clinical symptoms as well as sensory processing impairments similar to 75 
those observed in schizophrenia and exacerbates these symptoms in patients. Specifically, 76 
impairments in the P50, N100, and P300 components of the AEP as well as in oscillatory activity 77 
have been observed after acute administration of NMDAR agonists (Chen et al., 2015; Javitt, 2009; 78 
Krystal et al., 1994).  79 
     MMN, an AEP component generated by deviant stimuli within an oddball paradigm, has been 80 
extensively used to measure NMDAR dysfunction in schizophrenia and it is often found decreased 81 
in amplitude in both chronic schizophrenia and earlier stages of the disease (Coyle, 2012; 82 
Moghaddam and Javitt; 2012; Turetsky et al., 2007).  Previous studies have shown that 83 
administering NAC to chronic schizophrenia patients led to improved MMN responses (Lavoie et al., 84 
2008), and increased EEG synchronization (Carmeli et al., 2012), in addition to improvement of 85 
negative symptoms (Berk et al., 2008). NAC has been used in various studies as a cysteine donor 86 
and given orally is quickly absorbed; peak plasma concentration of cysteine is reached within 120 87 
mins (Borgstrom and Kagedal, 1990). NAC crosses the blood-brain barrier, and cysteine can be used 88 
in the brain as a GSH precursor (Farr et al., 2003; Conus et al., in revision). Animal studies have 89 
previously shown that administration of NAC protects the brain against GSH depletion (Atkuri et al., 90 
2007; Fu et al., 2006; Kamboj et al., 2006) and its neurochemical and morphological consequences 91 
(das Neves Duarte et al., 2012; Cabungcal et al. 2013). 92 
     Deficits in the P50 and N100 components of the AEPs are well established in patients with 93 
schizophrenia (Bodatsch et al., 2015; Brockhaus-Dumke et al., 2008; Rosburg et al., 2008). 94 
Schizophrenia patients show a significant diminution in the amplitude of N100, especially for long 95 
ISIs (>1 s) (Rosburg et al., 2008; Shelley et al., 1999). Two recent studies using an auditory oddball 96 
paradigm demonstrated that psychotic disorder patients show impairments in response to 97 
standard/frequent stimuli in both P50 and N100 (Geiser et al., 2017), as well as the alpha-frequency 98 
range, the latter of which is thought to reflect deficient thalamo-cortical connectivity (Lee et al., 99 
2017). The low-level AEP deficit observed by Geiser et al. resulted from weaker responses within 100 
the left temporo-parietal lobe and it was correlated with peripheral measures of GSH levels, 101 
specifically the ratio of glutathione peroxidase and glutathione reductase activities (GPx/GR) which 102 
correlates negatively with brain GSH levels in early psychosis patients (Xin et al., 2016). This AEP 103 
deficit in response to standard stimuli within the oddball sequence points to impaired input to 104 
auditory cortex (Lee et al., 2017). Previous studies have shown that the responses to standard 105 
sounds within oddball ERP tasks are impaired not only in chronic schizophrenia, but also in first–106 
episode schizophrenia patients and clinical high-risk individuals (Salisbury et al., 2010; del Re et al., 107 
2015). In addition, Foxe et al. (2011) demonstrated a significant amplitude reduction of the N100 in 108 
clinically unaffected first-degree relatives and highlighted the importance of the use of high 109 
numbers of trials for the reliable quantification of the evoked responses of interest. 110 
     In the present study, we investigated if the effect of NAC on MMN responses also applies to low-111 
level auditory deficits in psychosis, specifically to the reduced N100 response to standard sounds. 112 
Additionally, as the group of patients that participated in this study was in the early stages of the 113 
disease, we assessed whether the efficacy of NAC can extend to early psychosis (EP). We show for 114 
the first time, that NAC administration results in improved low-level auditory processing. 115 
116 
 2. Methods and materials 117 
2.1. Clinical Trial Protocol 118 
     NAC (2700 mg / day) and placebo were administered to EP patients for 6 months following a 119 
double-blinded, randomized design. Electroencephalographic (EEG) recordings and blood sampling 120 
were performed at the onset of the protocol (baseline measurements), and at the end of the study 121 
(after the 6 months of the NAC administration) (Swiss Medic (2008DR2308), ClinicalTrial.gov. 122 
(NCT01354132)).  123 
124 
2.2. Participants 125 
     Fifteen patients (13 men, 13 right-handed; aged 26±1.4 years; mean±SEM) meeting criteria for 126 
psychosis, as defined by the “Psychosis threshold” subscale of the Comprehensive Assessment of at 127 
Risk Mental States scale (CAARMS; Yung et al., 2005) at the baseline participated in this study. The 128 
patients were recruited from the Treatment and Early Intervention in Psychosis Program, (TIPP, 129 
University Hospital, Lausanne; Baumann et al., 2013), which is a 3 year program specialized in the 130 
treatment of early phase of psychosis that included patients that had not received more than 6 131 
months of previous treatment. The diagnosis was confirmed 3 years after the data acquisition 132 
(Table 2). The participants we report here are thus part of a larger clinical trial (Conus et al., in 133 
revision). Only the data from patients that completed the EEG sessions both before and after 134 
treatment are reported here.  Data from these patients at the onset of the protocol were compared 135 
with those from 18 gender and age-matched healthy controls (15 men, 16 right-handed; aged 136 
27.3±2 years) (Table 1). Healthy controls were assessed by the Diagnostic Interview for Genetic 137 
Studies (Preisig et al., 1999). Major mood, psychotic or substance-use disorder and having a first-138 
degree relative with a psychotic disorder were exclusive criteria for controls. All participants 139 
reported normal hearing. All participants provided their written, informed consent, and the 140 
procedures were approved by the local Ethics Committee. Some of the data collected in the 141 
baseline measurement were reported as part of a study focusing on low-level auditory impairments 142 
in EP patients (Geiser et al., 2017). 143 
     Among the 15 patients, 8 were among the group that received NAC, and the remaining 7 144 
received placebo. Following their recruitment, patients were given an ID number, and both patients 145 
and investigators were blinded until the time of analysis. Patients that received NAC and patients 146 
that received placebo did not differ in their clinical and demographic characteristics (Table 1). 147 
148 
2.3. Stimuli and task 149 
     Participants performed an active oddball detection paradigm. An active task ensured attention 150 
to the auditory modality and to the stimulus features. Such attention has been shown to enhance 151 
early ERP components (Woldorff et al., 1993). Their task was to press a button on a response pad as 152 
fast as possible when they heard infrequent stimuli. The frequent stimulus (70% of trials) was a 153 
1000Hz centrally-presented tone of 100ms duration. The infrequent stimuli (each type constituting 154 
10% of trials) varied in pitch (1200Hz), perceived lateralization (700μs inter-aural timing difference), 155 
or duration (150ms). All tones were presented at an intensity of 75 dB SPL at the ear. A central 156 
visual fixation cross was present throughout the experiment. All tones were presented with an 157 
average inter-stimulus-onset-interval of 916ms jittered with a maximum of ±67ms. Stimuli were 158 
presented over insert earphones (Etymotic model ER-4P; www.etymotic.com). Stimulus 159 
presentation and response recordings were controlled by E-Prime (www.pstnet.com/eprime). 160 
161 
2.4. EEG acquisition and pre-processing 162 
       Continuous EEG was acquired at 1024 Hz through a 64-channel Biosemi ActiveTwo system 163 
using the internal CMS/DRL loop as reference (www.biosemi.com). EEG data pre-processing and 164 
analyses were performed with Cartool (Brunet et al., 2011) and STEN 165 
(http://www.unil.ch/line/home/menuinst/about-the-line/software--analysis-tools.html). Prior to 166 
epoching, the EEG was filtered (low-pass 60Hz; high-pass 0.1Hz; 50Hz notch; using a second-order 167 
Butterworth filter with -12 db/octave roll-off that was computed linearly in both forward and 168 
backward directions to eliminate phase shifts). As the purpose of the current study was to establish 169 
whether NAC administration can improve low-level auditory sensory processing, we focused the 170 
analysis on AEPs to frequent stimuli. Analyses of MMN will appear in a separate forthcoming article. 171 
Peri-stimulus epochs for the frequent stimuli, spanning 100ms pre-stimulus to 500ms post-stimulus 172 
were averaged from each participant to calculate the AEPs. Epochs were rejected based on an 173 
automated artifact rejection criterion of ±80μV as well as visual inspection for eye blinks, eye 174 
movements or other sources of transient noise. Prior to group averaging, data at artefact 175 
electrodes from each subject were interpolated (Perrin et al., 1987). In addition, data were baseline 176 
corrected using the 100 ms pre-stimulus period and recalculated against the average reference. 177 
     For baseline recordings, the average number (± SEM) of accepted epochs was 1594±65 for 178 
controls and 1410±85 for patients. These values did not significantly differ. Furthermore, in the 179 
baseline the average number of accepted epochs was 1560±102 for patients that later on received 180 
NAC treatment and 1230±110 for patients that later on received placebo. Following NAC treatment, 181 
1302±110 trials were included. Following placebo treatment, 1359±168 trials were included. These 182 
values did not significantly differ. 183 
184 
2.5. AEP analyses 185 
     The AEP data were analysed within an electrical neuroimaging framework. Modulations in AEP 186 
strength (using Global Field Power, GFP) and topography (using global dissimilarity) were analysed 187 
separately as a function of time (Lehmann and Skrandies, 1980; Murray et al, 2008). Presentation of 188 
some voltage waveform data at specific electrodes are also included here as a function of time in 189 
order to provide readers with a sense of the general waveform shape and data quality. Analyses of 190 
voltage waveforms were not performed quantitatively given that they are reference-dependent 191 
(Murray et al., 2008). First, at the baseline, independent samples t-tests were performed between 192 
patients and healthy controls in order to verify that this group of patients exhibited impaired N100, 193 
as it has been demonstrated in a recent study from our group (Geiser et al., 2017). Second, mixed-194 
model ANOVAs with the patient group as a between-subject factor (NAC vs. placebo) and the time 195 
of measurement (Pre vs. Post treatment administration) as a within-subject factor were performed 196 
in order to assess whether 6 months of NAC administration improved low-level auditory processing. 197 
A temporal criterion for the detection of statistically significant effects was applied (>15 ms 198 
continuously at 1024 Hz sampling) in order to correct for temporal auto-correlation (Guthrie and 199 
Buchwald, 1991). 200 
201 
2.6. Source estimation and analyses 202 
    We estimated the underlying intracranial sources of the AEPs in response to the patient group 203 
and the time of measurement using a distributed linear inverse solution (minimum norm) 204 
combined with the LAURA (local autoregressive average) regularisation approach (Grave de Peralta 205 
Menendez et al., 2001, 2004; see also Michel et al., 2004 for a review). The solution space was 206 
calculated on a realistic head model that included 5013 nodes, selected from a grid equally 207 
distributed within the gray matter of the Montreal Neurological Institute’s average brain (courtesy 208 
of Grave de Peralta Menendez and Gonzalez Andino; http://www.electrical-neuroimaging.ch/). The 209 
head model and lead field matrix were generated within the Spherical Model with Anatomical 210 
Constraints (SMAC; Spinelli et al., 2000) as implemented in Cartool. As an output, LAURA provides 211 
current density measures; their scalar values were evaluated at each node. The time periods used 212 
for source estimation were determined from the topographic analyses. Statistical analysis of source 213 
estimations was performed by first taking the average of the AEP across the N100 component 214 
(which was identified over the 52–140ms interval based on spatial correlation as a function of time 215 
(Michel and Murray, 2012). Then, the estimation of the source activity for this averaged time period 216 
was performed in two a priori defined regions known to participate in N100 generation, one in the  217 
left and one in the right posterior superior temporal cortex. Each of these regions included 49 218 
solution points (see Figure 3). After that an ANOVA for the between subject factor of patient group 219 
and the within subject factor of time of measurement was conducted on the source estimations of 220 
each region.  221 
222 
3. Results 223 
3.1. Baseline measurements: Controls vs. Patients 224 
     Patients compared to controls showed a weaker auditory response to frequent stimuli at 225 
P50/N100 and at later time windows (52-140, 163-463ms) as measured qualitatively at individual 226 
frontal electrodes (F3 and F4) as well as quantitatively through statistical analysis of GFP (Figure 1). 227 
This is consistent with the results of Geiser et al., 2017 from which a subgroup of patients was 228 
included here. No significant topographic differences were found between groups quantified by 229 
global dissimilarity.  230 
231 
3.2.1. Treatment efficacy: NAC vs. Placebo 232 
     Group-averaged AEPs for the two treatment groups, before and after treatment are displayed in 233 
Figure 2 from two exemplar frontal electrodes (F3, F4). A mixed-model ANOVA on the GFP as a 234 
function of time showed a significant interaction between time of measurement and patient group 235 
over the time periods 70-86ms, 100-120ms and 270-371ms. Post-hoc paired t-tests were conducted 236 
for each treatment group separately. A significant effect of treatment was observed for the NAC 237 
group over the time periods: 75-95, 106-126, 178-198, 283-303 and 312-342ms. No reliable 238 
differences were observed for the placebo group. Analysis of dissimilarity revealed no significant 239 
topographic differences between the different conditions or groups.   240 
     Statistical contrasts of the mean source activity calculated over the 52-140ms time period for the 241 
left posterior superior temporal cortex showed a significant interaction between treatment group 242 
and time of measurement (F= 5.11, p< .05, η2=0.28) (Figure3). Post-hoc t-tests showed that source 243 
activity was significantly stronger for the Post-NAC than Pre-NAC treatment within the left temporal 244 
cortex (t=-2.5, p<. 05). In contrast, no differences were found in the placebo group before and after 245 
treatment. In the right posterior superior temporal cortex, there was no significant interaction 246 
between treatment group and time of measurement (F=0.06, p= 0.8). 247 
248 
4. Discussion 249 
 This study demonstrated that administration of the GSH precursor NAC improves early auditory 250 
ERP deficits in patients during the early psychosis. It has been previously shown that apart from 251 
MMN deficits, there is a general early auditory impairment in psychotic disorder patients, 252 
manifested as a significantly weaker response to standard sounds during an auditory oddball 253 
paradigm (Geiser et al., 2017; Lee et al., 2017; del Re et al., 2015; Salisbury et al., 2010). This was 254 
again the case for our patients at protocol onset; patients’ AEPs were significantly weaker than 255 
those from healthy controls 52-140ms post-stimulus onset encompassing the P50/N100 complex. 256 
This result contrasts with some previous studies that have used a similar auditory oddball paradigm 257 
in chronic schizophrenia patients and have demonstrated impaired MMN generation, but intact 258 
AEP amplitude in general around N100 (Lavoie et al., 2008). This discrepancy between our findings 259 
and the previous results could be due to that this general auditory impairment within the oddball 260 
paradigm is specific to earlier stages of the disease and later on it recovers or is otherwise 261 
compensated for. However, there are a few studies showing that N100 is reduced in chronic 262 
schizophrenia especially when long ISIs are used, which makes this account less plausible (Bodatsch 263 
et al., 2015; Javitt & Sweet, 2015; Rosburg et al., 2008). Alternatively, the discrepancy between our 264 
results and the Lavoie et al., 2008 findings could be due to differences in the number of trials that 265 
were used, and therefore in signal-to-noise. In the current study we used a very large number of 266 
trials per subject (>1500 trials) which led to a high signal-to-noise for the N100 component and 267 
arguably minimized false negative findings. This highlights the importance of acquiring large 268 
numbers of trials in individual patients. As most of the previous studies using auditory oddball 269 
paradigms have focused on the MMN component, further work is needed in order to clarify the 270 
pattern of deficits across stages of the disease.  271 
     The critical finding of our study is that add-on administration of NAC for an extended period of 272 
time (6 months), improved the generation of early AEPs. This is the first study showing an 273 
improvement of low-level auditory processing by NAC. Previous clinical trials administering NAC to 274 
chronic schizophrenia patients had shown improved MMN generation, but no changes in AEP 275 
amplitude in general (though it must be emphasized that such was not impaired to start with at 276 
least in their small group of chronic patients) (Lavoie et al., 2008). Add-on administration of NAC 277 
similar to that used here has been shown to result in increased GSH levels in the blood, though 278 
without concomitant increases in cysteine (at least at the doses we have used). That said, there is 279 
evidence to support NAC leading to increased brain levels of GSH in humans (Conus et al., in 280 
revision) as well as in mice during periods of oxidative stress (Farr et al., 2003; Lante et al., 2008; 281 
das Neves Duarte, 2012). Given the evidence that GSH can potentiate NMDAR functioning 282 
(Hardingham and Do, 2016) alongside evidence for the role of NMDAR in generation of auditory 283 
AEPs (Javitt, 2015 for review), we speculate that NAC administration here is exerting its positive 284 
effect via NMDAR activity. 285 
     It is well established that the N100 is generated by neural populations in the primary and 286 
association auditory cortices (Godey et al., 2001; Zouridakis et al., 1998) as well as frontal sources 287 
(Deouell et al., 1998; Giard et al., 1990; De Santis et al., 2007). The AEP improvements following 288 
NAC treatment resulted from changes in ERP strength but not topography, suggestive of general 289 
amplitude or gain modulations rather than compensatory network activity. Consistently, the 290 
source-localization here revealed that the improvement following NAC administration in the 291 
P50/N100 complex was the result of stronger activity in the left temporal cortex; regions well 292 
established as underlying the N100 response. In contrast, the placebo group did not demonstrate 293 
changes in the amplitude of brain activity 6 months after the first testing session within either left 294 
or right temporal cortices. This finding highlights the potential value of NAC in the treatment of 295 
psychosis, in remediating impaired responses in auditory cortices. It is worth noting that 296 
electrophysiological improvements following NAC administration seem to coincide with 297 
biochemical and neurocognitive improvements observed in an investigation of a larger sample than 298 
the limited set of patients studied here (Conus et al., in revision). Specifically, in this larger cohort of 299 
patients, it was shown that administration of NAC led to increased glutathione levels in the brain 300 
(levels of GSH in medial prefrontal cortex were assessed by H-MRS on a 3T MR scanner) and 301 
improved speed of processing (assessed with the MATRICS Consensus Cognitive Battery). AEP 302 
effects seem to be particularly robust, even in small samples and in analyses of individual patients 303 
and therefore are particularly promising as trait/state markers. For example, in Lavoie et al. (2008) 304 
AEP effects after add-on NAC administration in chronic patients preceded improvements in clinical 305 
scores by at least 2 months (Lavoie et al., 2008; Berk et al., 2008). The present study extends such a 306 
pattern to demonstrate NAC efficacy even in the early stages of the disease. 307 
308 
     In summary, we show results indicating that long-duration treatment with NAC improves low-309 
level auditory processing deficits over the N100 time period in this sample of EP patients.  However, 310 
the small size of the sample of patients limits the generalisability of our findings. In order to 311 
establish the effects of NAC on low-level auditory processing in early psychosis a replication of 312 
these findings in a larger sample of patients is needed. Nonetheless, the present data contribute to 313 
a growing body of evidence on the efficacy of such add-on treatments, particularly for low-level 314 
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500 
Figure Captions 502 
Figure 1. Group-averaged voltage waveforms from frontal sites F3 and F4 as well as global field 503 
power (GFP) waveforms from control subjects and early psychosis patients (black and blue 504 
traces, respectively). The grey areas in the GFP waveforms indicate significant differences as a 505 
function of time. Responses were weaker in patients. 506 
Figure 2. Group-averaged voltage waveforms from frontal sites F3 and F4 as well as GFP waveforms 507 
from patients who received NAC and placebo treatment (panels A and B, respectively). Gray 508 
traces display responses pre-treatment and red traces responses post-treatment. Insets display 509 
the difference topography averaged over the 52-140ms period. Blue arrows indicate the 510 
significant differences before and after NAC treatment over the N100 period. 511 
Figure 3. Results of the mixed ANOVA on the mean source activity on the predefined left temporal 512 
cortex region. Asterisks indicate significant differences between pre and post-treatment for the 513 
patients that received NAC. Source activity was estimated on data averaged over the 52-140ms 514 
period. Inset indicates the selected points for the left hemisphere (pink nodes). A symmetric 515 
set of points was tested in the right hemisphere. 516 
Table 1: Demographic and clinical characteristics of psychosis disorder patients that received NAC 
(n=8) and patients that received placebo treatment (n=7) at baseline. Mean and standard error are 
indicated.  
 NAC treatment   Placebo treatment 
  patients    patients    p values 
Daily Chlorpromazine (CPZ)-equivalent [mg/day] 385.5 ±100 397.13±111     p=.94 
Education of patients in years 12.42±0.89 11.42±1.04      p=.58 
PANSS: Positive Symptoms 16.6±1.6 15.3±1.3           p=.56 
PANSS: Negative Symptoms 15.5±1.8 17.4±2.8           p=.57 
PANSS: Total 68.62±5.4 69.14±5.5        p=.95 
Time lapse between psychosis threshold and EEG recordings in days 783 ±255 771 ±280         p=.97 
Table(s)
Table 2: Specific diagnosis of patients after 3 years and antipsychotic medication at the 
time of the experiment (separately for the groups following NAC and placebo treatment) 
Antipsychotic medication   Number of  
NAC patients 
Number of  
 Placebo patients 
Aripiprazole 1 1 
Olanzapine 2 
Quetiapine 3 1 
Risperidone 1 1 
None 3 2 
Diagnoses 
Schizophrenia undifferentiated 2 2 
Schizophrenia, paranoid type 4 2 
Schizotypical personality disorder 1 1 
Recurrent depressive disorder with psychotic 
features 
1 
Schizo-affective disorder, bipolar type 1 
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